Anakinra is recombinant interleukin (IL)-1 receptor antagonist. A new study published in Arthritis & Rheumatism online has found that anakinra is safe and effective for severe Muckle-Wells syndrome.
The researchers investigated the efficacy of anakinra in 12 patients with severe Muckle Wells syndrome. Seven patients were adults and five were children.
All constitutional symptoms resolved by 2 weeks, and there was near complete resolution of musculoskeletal manifestations and significant improvement in ocular symptoms and skin manifestations.
Treatment was well tolerated, and no serious adverse events were observed.
The authors concluded that Anakinra was a safe and effective treatment for severe Muckle Wells syndrome, leading to a significant improvement of disease activity at 2 weeks and long-term.
The authors recommend that Anakinra therapy should be considered in children and adults with severe MWS disease requiring IL-1 blockade.
Popularity: 1% [?]
[...] Anakinra is an interleukin 1 receptor antagonist and has been found to lead to an improvement in the hearing loss. A recent study has also fund it useful in treating musculoskeletal manifestation. [...]